Bromantane
How bromantane may affect dopamine synthesis, why it was used for asthenia, what people report, and where the human evidence runs out.
Open dossier →
9-ME-BC
MAO activity, exciting preclinical dopamine claims, and the massive gap between animal studies and actual human data.
Open dossier →
Dihexa
Dihexa looked fascinating until the research underneath it fell apart. This review starts with the retractions, then covers the remaining claims and unanswered safety risks.
Open dossier →
Nefiracetam
Calcium-channel activity, small post-stroke apathy studies, and the dog toxicity findings that make the safety picture hard to ignore.
Open dossier →
TAK-653
Early human safety and pharmacology data, promising animal research on plasticity, and no solid proof yet that TAK-653 improves cognition or mood.
Open dossier →
GB-115
A Russian anxiolytic candidate with an interesting CCK2 mechanism, small clinical studies, and very little independent research to confirm the claims.
Open dossier →
NSI-189
NSI-189 missed its main endpoint in phase 2, but secondary cognitive signals kept it interesting. This profile covers those results and the still-unclear biology.
Open dossier →
ACD856
An early-stage neurotrophin drug with phase 1 safety and pharmacokinetic data, lots of preclinical claims, and an exact chemical structure the developer has not disclosed.
Open dossier →
Telmisartan
A well-supported blood-pressure drug with less certain claims around athletic use and PPARγ activity. Useful evidence, weak extrapolations, and the safety details that matter.
Open dossier →
rhGH / Growth Hormone
What growth hormone reliably treats, what body-composition trials actually show, where performance claims fall short, and why systemic risk gets serious fast.
Open dossier →
Trenbolone
No controlled human trials and a brutal evidence gap. This profile separates case reports, animal data, and established AAS-class harms from gym lore.
Open dossier →
Equipoise
A long-acting veterinary androgen with almost no direct human research. Most of the safety picture comes from animal data, case reports, and established anabolic-steroid harms.
Open dossier →
Cardarine
Short human studies suggest changes in blood lipids, not proven performance gains. The unresolved rodent cancer findings are the part nobody should hand-wave away.
Open dossier →